Isconova AB appoints Lena Söderström as new CEO

25-Aug-2009 - Sweden
Isconova AB has appointed a new CEO, Lena Söderström, who will succeed Bengt Falk on 1 November 2009. Lena Söderström is currently CEO at Kibion AB. Kibion AB is a company focused on the commercialization of H. pylori diagnostic products and is a subsidiary of the publicly listed company Orexo AB. Kibion has products commercialized on a global basis. Lena has built Kibion from ‘start up’ to a business operating through distributors in the global marketplace. Lena Söderström has more than 20 years of management experience in the international pharmaceutical and medical device industry and vast experience in development as well as production and marketing. Before joining Kibion she was Director business development at Fresenius Kabi AB. After 7 years as CEO, Bengt Falk has decided to leave the company. During Bengt Falk management the company has developed into a leading manufacturer of adjuvant for veterinary vaccines and the foundation is laid for the development of the company’s technology into human vaccines through the successful Phase 1 trial of a pandemic influenza vaccine and significant license and supply deals.

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances